Wealth Advisors of Tampa Bay LLC Sells 49,306 Shares of Pfizer Inc. $PFE

Wealth Advisors of Tampa Bay LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 33.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 98,094 shares of the biopharmaceutical company’s stock after selling 49,306 shares during the quarter. Wealth Advisors of Tampa Bay LLC’s holdings in Pfizer were worth $2,443,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Horizon Financial Services LLC grew its position in shares of Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares in the last quarter. YANKCOM Partnership bought a new position in shares of Pfizer during the 4th quarter worth $28,000. HFM Investment Advisors LLC grew its position in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares in the last quarter. Darwin Wealth Management LLC bought a new position in shares of Pfizer during the 2nd quarter worth $32,000. Finally, Torren Management LLC bought a new position in shares of Pfizer during the 4th quarter worth $34,000. Institutional investors own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Several recent articles highlight bullish arguments for Pfizer, including analyst optimism around late-stage pipeline assets and the view that the stock could still have meaningful upside if upcoming drug trials and launches deliver. Article Title
• Positive Sentiment: Coverage also points to Pfizer’s attractive dividend yield and argues the payout remains supported, which may appeal to income-focused investors even while growth is uneven. Article Title
• Positive Sentiment: An article on Pfizer’s abrocitinib atopic dermatitis study nearing a data milestone suggests a near-term catalyst that could improve sentiment if results are favorable. Article Title
• Neutral Sentiment: One piece frames Pfizer as a “best medical stock” idea based on billionaire interest, but that is more of a screening-style thesis than a direct new company-specific catalyst. Article Title
• Neutral Sentiment: Another article says Pfizer’s investment narrative is shifting, with fair value estimates and analyst targets reflecting both pipeline hopes and revenue concerns, indicating a split Wall Street view rather than a clear breakthrough. Article Title
• Negative Sentiment: The biggest headwind is the Eliquis patent cliff, with projected multi-year revenue losses that could weigh on Pfizer’s future sales and earnings if new products do not offset the decline. Article Title

Pfizer Price Performance

Shares of PFE stock opened at $25.86 on Wednesday. Pfizer Inc. has a 1-year low of $23.06 and a 1-year high of $28.75. The stock’s 50-day moving average is $26.82 and its 200 day moving average is $26.26. The company has a market cap of $147.39 billion, a P/E ratio of 19.74 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter last year, the company earned $0.92 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on PFE shares. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, February 4th. Royal Bank Of Canada reissued an “underperform” rating and set a $25.00 price target on shares of Pfizer in a research report on Monday, April 20th. Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a research report on Thursday, February 12th. Finally, Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a research report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $28.61.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.